GeneHealth - Your precision medicine

Myoma

Disease Details

Family Health Simplified

Buy Membership

Description: Myoma, also known as a uterine fibroid, is a non-cancerous growth of the uterus that often appears during childbearing years.
Type: Myomas, also known as uterine fibroids, are non-cancerous tumors that develop in or on the uterus. They are generally classified into four types based on their location:
1. Intramural: Within the muscular wall of the uterus.
2. Subserosal: On the outer wall of the uterus.
3. Submucosal: Just under the lining of the uterine cavity.
4. Pedunculated: Attached to the uterus by a stalk.

Genetic Transmission: The exact cause of myomas isn't fully understood, but they are influenced by genetic factors. A family history of fibroids can increase the risk, implicating a hereditary component. However, the pattern of genetic transmission isn't typically classified under simple Mendelian inheritance patterns but rather involves multiple genes and gene-environment interactions.
Signs And Symptoms: Myoma, also known as uterine fibroids, can present with the following signs and symptoms:

- Heavy menstrual bleeding
- Menstrual periods lasting more than a week
- Pelvic pressure or pain
- Frequent urination
- Difficulty emptying the bladder
- Constipation
- Backache or leg pains
- Pain during intercourse

In some cases, myomas may be asymptomatic and discovered incidentally during a pelvic exam or imaging studies.
Prognosis: The prognosis for myomas, commonly known as uterine fibroids, is generally favorable. These benign tumors of the uterus are not cancerous, and many women with myomas experience no symptoms. The growth rate can vary; some fibroids remain stable in size, while others may grow or shrink, especially after menopause. Symptoms, if present, may include heavy menstrual bleeding, pelvic pain, and pressure symptoms. Treatment options can range from watchful waiting to medical or surgical interventions, depending on symptom severity and patient preferences. Regular follow-ups with a healthcare provider are typically recommended to monitor the condition.
Onset: The onset of myomas, also known as uterine fibroids, often occurs during a woman's reproductive years, most commonly in her 30s and 40s. The exact cause is not well understood, but they are thought to be influenced by genetic, hormonal, and environmental factors.
Prevalence: Myomas, also known as uterine fibroids, are quite common. It is estimated that about 70-80% of women will develop fibroids by the age of 50. However, many cases are asymptomatic, and only about 20-30% of women with fibroids will have symptoms severe enough to require treatment.
Epidemiology: Myomas, also known as uterine fibroids, are the most common benign tumors of the female reproductive system. They are composed of smooth muscle cells and fibrous connective tissue and occur in the uterus. Epidemiologically, myomas are observed most frequently in women of reproductive age, particularly between the ages of 30 and 50. They are more common among African American women, who also tend to have larger and more numerous fibroids compared to women of other ethnic groups. The exact cause of myomas is not well understood, but their development is believed to be related to hormonal factors, particularly estrogen and progesterone. Risk factors include family history, obesity, and early onset of menstruation.
Intractability: Myomas, also known as uterine fibroids, are generally not considered intractable. They are benign tumors of the uterus that can often be managed with various treatments, including medication, non-invasive procedures, and surgical options such as myomectomy or hysterectomy, depending on the severity and symptoms. However, the response to treatment can vary from person to person.
Disease Severity: **Disease Severity**
The severity of myomas, also known as uterine fibroids, can vary widely among individuals. They can be asymptomatic and go unnoticed or cause significant symptoms that impact the quality of life. Symptoms may include heavy menstrual bleeding, pelvic pain, and reproductive issues.

**Nan (Not Applicable)**
The term "nan" might refer to "not a number" in data terms, but if you meant something else, please clarify.
Healthcare Professionals: Disease Ontology ID - DOID:2691
Pathophysiology: Myoma, also known as uterine fibroids, are benign tumors that originate from the smooth muscle layer (myometrium) of the uterus. The pathophysiology of myomas involves a complex interplay of genetic, hormonal, and environmental factors.

1. **Genetic Influences**: Certain genetic mutations and hereditary factors increase the risk of developing myomas. Specific genes are found to be overexpressed in myoma tissues.

2. **Hormonal Factors**: Estrogen and progesterone play a crucial role in the growth of myomas. These hormones promote the proliferation of smooth muscle cells and extracellular matrix components.

3. **Growth Factors**: Myomas show increased expression of growth factors (e.g., transforming growth factor-beta, basic fibroblast growth factor), which stimulate cell proliferation and matrix deposition.

4. **Extracellular Matrix**: Myomas have an altered composition of the extracellular matrix, including increased collagen deposition, which contributes to their growth and rigidity.

Myomas can vary in size and location and may cause symptoms such as heavy menstrual bleeding, pelvic pain, and reproductive issues, although many are asymptomatic.
Carrier Status: Myoma, also known as uterine fibroids, are benign tumors that develop from the muscle tissue of the uterus. Information regarding carrier status is not applicable to myoma, as they are not caused by a transmissible pathogen or a single genetic mutation that would classify someone as a carrier.
Mechanism: Myoma, also known as uterine fibroids, are benign smooth muscle tumors of the uterus. Their exact mechanisms and molecular mechanisms involve a combination of genetic, hormonal, and environmental factors:

**Mechanism:**
1. **Hormonal Influence:** Estrogen and progesterone, the primary female sex hormones, promote the growth of fibroids. These hormones stimulate the proliferation of smooth muscle cells and the production of extracellular matrix.
2. **Genetic Factors:** Certain genetic mutations and familial predispositions can increase the risk of developing fibroids.

**Molecular Mechanisms:**
1. **Signaling Pathways:** Various signaling pathways are implicated in myoma development, such as the Wnt/β-catenin, PI3K/AKT, and TGF-β pathways. These pathways regulate cell proliferation, differentiation, and extracellular matrix production.
2. **Growth Factors:** Overexpression of growth factors like transforming growth factor-beta (TGF-β), insulin-like growth factor (IGF), and fibroblast growth factor (FGF) contributes to fibroid growth.
3. **Genetic Aberrations:** Specific chromosomal changes, including rearrangements and mutations in genes like MED12, HMGA2, and COL4A5, have been identified in fibroid tissues.
4. **Extracellular Matrix:** Fibroids are characterized by an excessive accumulation of extracellular matrix components, such as collagen, fibronectin, and proteoglycans, which contribute to the stiffness and fibrous nature of the tumors.

Understanding these mechanisms is crucial for developing targeted therapies and improving management strategies for myoma.
Treatment: Myoma, also known as uterine fibroids, can be treated through various methods depending on the severity of symptoms, size, and location of the fibroids, as well as the patient's desire for fertility. Treatments include:

1. Medication:
- Gonadotropin-releasing hormone (GnRH) agonists to shrink fibroids.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) for pain relief.
- Oral contraceptives or progestins to regulate bleeding.
- Tranexamic acid to reduce heavy menstrual bleeding.
- Anti-hormonal agents.

2. Minimally Invasive Procedures:
- Uterine artery embolization (UAE) to reduce blood flow to the fibroid and shrink it.
- MRI-guided focused ultrasound surgery (FUS) to destroy fibroid tissue.

3. Surgical Options:
- Myomectomy to remove fibroids while preserving the uterus.
- Hysterectomy to remove the uterus, which is a definitive solution for fibroids but ends fertility.

4. Lifestyle and Other Measures:
- Dietary changes and exercise might help manage symptoms.

These treatments can vary based on individual circumstances and should be discussed with a healthcare provider.
Compassionate Use Treatment: For myoma (uterine fibroids), "compassionate use" treatments and off-label or experimental options can include:

1. **Ulipristal Acetate**: Typically used for emergency contraception, it may be prescribed off-label to manage fibroid symptoms and reduce their size.

2. **MRI-Guided Focused Ultrasound Surgery (MRgFUS)**: Though not standard, this non-invasive technique uses focused ultrasound waves to heat and destroy fibroid tissue.

3. **Radiofrequency Ablation (RFA)**: This minimally invasive procedure uses radiofrequency energy to shrink fibroids and is considered experimental in some circles.

4. **Mifepristone**: A medication usually used for medical termination of pregnancy, mifepristone can be prescribed off-label to reduce fibroid size and symptoms.

5. **GnRH Antagonists (e.g., Elagolix)**: These drugs are used to reduce the size and symptoms of fibroids but are considered off-label for this purpose.

Always consult a healthcare provider to discuss the potential benefits and risks of these treatments.
Lifestyle Recommendations: For managing myoma (uterine fibroids), here are some lifestyle recommendations:

1. **Healthy Diet**:
- Focus on a diet rich in fruits, vegetables, whole grains, and lean proteins.
- Limit red meat and high-fat dairy products, which may exacerbate symptoms.

2. **Weight Management**:
- Maintain a healthy weight; obesity can increase the risk and severity of fibroids.

3. **Physical Activity**:
- Engage in regular exercise to improve overall health and potentially reduce symptom severity.

4. **Stress Management**:
- Practice stress-reducing techniques such as yoga, meditation, or deep-breathing exercises.

5. **Avoiding Toxins**:
- Minimize exposure to environmental toxins and endocrine disruptors like BPA (found in some plastics) and certain pesticides.

6. **Limit Alcohol and Caffeine**:
- Reduce intake of alcohol and caffeine, as these can exacerbate symptoms.

7. **Monitor Symptoms**:
- Keep track of symptoms and consult with a healthcare provider regularly to monitor the condition.

These lifestyle changes may help manage symptoms and improve overall health, but always consult a healthcare provider for personalized advice.
Medication: Medications for uterine myomas (fibroids) aim to manage symptoms and reduce their size. These can include:

1. **Gonadotropin-releasing hormone (GnRH) agonists**: These can shrink fibroids by lowering estrogen and progesterone levels.
2. **Progestin-releasing intrauterine device (IUD)**: This helps alleviate heavy bleeding and pain.
3. **Tranexamic acid**: Used to reduce heavy menstrual bleeding.
4. **Nonsteroidal anti-inflammatory drugs (NSAIDs)**: These help relieve pain.
5. **Oral contraceptives**: These can regulate menstrual cycles and reduce heavy bleeding.
6. **Selective progesterone receptor modulators (SPRMs)**: These can help reduce bleeding and shrink fibroids.

Consult a healthcare professional for personalized treatment options.
Repurposable Drugs: Myoma, also known as uterine fibroids, are noncancerous growths in the uterus that commonly appear during childbearing years. There hasn't been a significant development specifically listing repurposable drugs for myoma treatment. Typically, treatment options involve hormonal medications such as GnRH agonists, oral contraceptives, anti-hormonal agents, and non-steroidal anti-inflammatory drugs (NSAIDs) to manage symptoms. For more advanced cases, surgical options like myomectomy or hysterectomy might be recommended.

Nan refers to "Not Applicable" or "Not Available" in contexts where specific information is missing. Therefore, no further information is provided under that term for myoma.
Metabolites: Myomas, also known as uterine fibroids, are benign tumors of the uterus. The metabolites associated with uterine fibroids include hormones such as estrogen and progesterone, which can influence their growth. Other metabolites may include:

1. Prostaglandins: These are lipid compounds that can affect inflammation and blood flow within the uterus.
2. Fibronectin and Collagen: These are extracellular matrix proteins that contribute to the structural integrity of the fibroids.
3. Lactate and Pyruvate: Byproducts of glycolysis due to the altered metabolic environment of the fibroid tissue.

These metabolites can vary in concentration and influence the development, growth, and symptoms associated with myomas.
Nutraceuticals: There is limited evidence to suggest that specific nutraceuticals can effectively treat or manage myomas (uterine fibroids). However, some studies suggest that Vitamin D, green tea extract, and curcumin may have beneficial effects on fibroid growth and symptoms. Always consult with a healthcare professional before starting any new treatment. Nanotherapy, which refers to the use of nanoparticles for targeted treatment delivery, is still in the experimental stages for myoma treatment but holds promise for the future.
Peptides: Myoma, also known as a uterine fibroid, is a benign tumor that develops from the smooth muscle tissue of the uterus.

**Peptides**: There is ongoing research into the role of various bioactive peptides in the development and potential treatment of myomas. Peptides could potentially regulate cell growth, apoptosis, and other cellular processes involved in myoma formation. Specific therapeutic peptides are being studied for their ability to target and inhibit the growth of fibroid cells.

**Nan**: Nanotechnology is being explored as a novel approach for the diagnosis and treatment of myomas. Nanoparticles can be engineered to deliver therapeutic agents, such as drugs or genetic material, directly to the fibroid cells, minimizing side effects and improving treatment efficacy. Nanoparticles also hold promise for enhanced imaging techniques to better visualize fibroids.